A DRUG INTERACTION STUDY EVALUATING THE COADMINISTRATION OF GS-9450, A NOVEL CASPASE INHIBITOR, AND THE FIXED-DOSE COMBINATION OF EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE IN HEALTHY VOLUNTEERS

被引：0
|
作者：
Cornpropst, M. T. [1 ]
Liang, W. [2 ]
Yuen, G. J. [1 ]
Eade, D. [1 ]
Hui, J. [3 ]
Hirsch, K. R. [4 ]
Findlay, J. W. [1 ]
机构：
[1] Gilead Sci Inc, Clin Pharmacol, Durham, NC USA
[2] Gilead Sci Inc, Biometr, Durham, NC USA
[3] Gilead Sci Inc, Bioanalyt, Durham, NC USA
[4] Gilead Sci Inc, Clin Res, Durham, NC USA
来源：
JOURNAL OF HEPATOLOGY | 2010年 / 52卷
关键词：
D O I：
10.1016/S0168-8278(10)60747-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S290 / S290
页数：1
相关论文
共 15 条
  • [11] Emtricitabine/tenofovir (Truvada®) fixed-dose combination in pre-exposure prophylaxis of human immunodeficiency virus: An observational drug utilization study using the French national health insurance database
    de Gage, Sophie Billioti
    Raguideau, Fanny
    Rudnichi, Annie
    Dray-Spira, Rosemary
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 496 - 496
  • [12] Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
    Orrell, Catherine
    Hagins, Debbie P.
    Belonosova, Elena
    Porteiro, Norma
    Walmsley, Sharon
    Falco, Vicenc
    Man, Choy Y.
    Aylott, Alicia
    Buchanan, Ann M.
    Wynne, Brian
    Vavro, Cindy
    Aboud, Michael
    Smith, Kimberly Y.
    LANCET HIV, 2017, 4 (12): : E536 - E546
  • [13] Efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed-dose combination (FDC) compared with ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive women with HIV-1 infection (ARIA study): subgroup analyses
    Johnson, Margaret
    Gatey, Caroline
    Manosuthi, Weeraweet
    Lazzarin, Adriano
    Podzamczer, Daniel
    Man, Choy
    Aylott, Alicia
    Buchanan, Annie
    Wynne, Brian
    Vavro, Cindy
    Aboud, Michael
    Smith, Kim
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [14] Superior efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) compared with ritonavir (RTV) boosted atazanavir (ATV) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatmentnai naive women with HIV-1 infection (ARIA Study)
    Orrell, C.
    Hagins, D.
    Belonosova, E.
    Porteiro, N.
    Walmsley, S.
    Falco, V.
    Man, C.
    Aylott, A.
    Buchanan, A.
    Wynne, B.
    Vavro, C.
    Aboud, M.
    Smith, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [15] Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study (vol 4, pg e546, 2017)
    Orrell, C.
    Hagins, D. P.
    Belonosova, E.
    LANCET HIV, 2017, 4 (12): : E535 - E535
12